Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

PR Newswire 1 hour ago

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

PR Newswire 6 days ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire June 7, 2024

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

PR Newswire June 5, 2024

Insmed to Host Commercial Webinar on June 4, 2024

PR Newswire May 30, 2024

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

PR Newswire May 30, 2024

Insmed Announces Proposed $500 Million Public Offering of Common Stock

PR Newswire May 28, 2024

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

PR Newswire May 28, 2024

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

PR Newswire May 27, 2024

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session

PR Newswire May 20, 2024

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

PR Newswire May 9, 2024

Insmed To Present at the BofA Securities Health Care Conference 2024

PR Newswire May 7, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire May 3, 2024

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

PR Newswire April 25, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 5, 2024

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

PR Newswire March 27, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire March 5, 2024

Insmed To Present at Three March Conferences

PR Newswire February 29, 2024

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

PR Newswire February 28, 2024

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

PR Newswire February 22, 2024